Generali Investments CEE investicni spolecnost a.s. Has $4.67 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX

Generali Investments CEE investicni spolecnost a.s. trimmed its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 10,491 shares of the pharmaceutical company’s stock after selling 539 shares during the period. Generali Investments CEE investicni spolecnost a.s.’s holdings in Vertex Pharmaceuticals were worth $4,671,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of VRTX. Brighton Jones LLC grew its position in Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after purchasing an additional 579 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 49.5% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,834 shares of the pharmaceutical company’s stock valued at $889,000 after acquiring an additional 607 shares in the last quarter. 180 Wealth Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at about $224,000. NBC Securities Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at about $167,000. Finally, LVW Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 3.7% during the 1st quarter. LVW Advisors LLC now owns 794 shares of the pharmaceutical company’s stock valued at $385,000 after acquiring an additional 28 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs bought 5,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was bought at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the purchase, the director owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VRTX. Canaccord Genuity Group decreased their target price on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating on the stock in a research report on Wednesday, August 6th. Wells Fargo & Company upgraded shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price on the stock in a research report on Wednesday, August 6th. JPMorgan Chase & Co. lifted their target price on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an “overweight” rating in a research report on Monday, July 14th. Leerink Partners upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their target price for the company from $458.00 to $456.00 in a research report on Thursday, September 25th. Finally, Leerink Partnrs upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 25th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $493.81.

Vertex Pharmaceuticals Stock Down 0.9%

NASDAQ:VRTX opened at $391.64 on Wednesday. The firm has a market cap of $100.41 billion, a PE ratio of 27.99 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The company’s 50-day moving average price is $403.17 and its two-hundred day moving average price is $444.73.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same period in the previous year, the business earned ($12.83) earnings per share. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.